1.03
+0.01(+0.98%)
Currency In USD
| Previous Close | 1.02 |
| Open | 1.01 |
| Day High | 1.04 |
| Day Low | 1 |
| 52-Week High | 5.95 |
| 52-Week Low | 0.81 |
| Volume | 166,274 |
| Average Volume | 1.02M |
| Market Cap | 11.12M |
| PE | -0.76 |
| EPS | -1.35 |
| Moving Average 50 Days | 1.01 |
| Moving Average 200 Days | 1.41 |
| Change | 0.01 |
If you invested $1000 in Marker Therapeutics, Inc. (MRKR) 10 years ago, it would be worth $14.55 as of October 21, 2025 at a share price of $1.03. Whereas If you bought $1000 worth of Marker Therapeutics, Inc. (MRKR) shares 5 years ago, it would be worth $63.58 as of October 21, 2025 at a share price of $1.03.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
GlobeNewswire Inc.
Oct 06, 2025 11:30 AM GMT
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment OTS product was well tolerated - safety data consistent with other MAR-T cell s
Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Aug 28, 2025 12:00 PM GMT
HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and so
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
GlobeNewswire Inc.
Aug 26, 2025 11:00 AM GMT
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating complete response (CR) Favorable safety profile o